Happy relationships protect heart health as strongly as traditional risk factors, but most cardiac care ignores this ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM ...

The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with ...

Nurse scientist Linda Park, PhD, uses NIH funding to study cardiac rehab and digital tools—like pedometers and apps—to ...

TUESDAY, Dec. 16, 2025 (HealthDay News) — Hearts are often associated with love, especially around Valentine’s Day. That’s ...

Strong affinity in relationships may heal hearts. Treating the heart while fostering connections is vital for long-term well-being in heart patients.

The support of a beloved partner can dramatically improve recovery for people who've had a heart attack or other heart-related emergency.

Financial strain and food insecurity show up as the strongest drivers of accelerated cardiac aging and higher risk of death.

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approv ...

The U.S. Food and Drug Administration has approved Cytokinetics' oral drug to treat a rare heart condition, the company said ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...